Delta-Fly Pharma,Inc. [4598.T]
TOKYO, Apr 15 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) reported progress on its ongoing Phase 2/3 clinical trial for DFP17,729.
As of now, the Phase 2 portion of the study is being conducted across 16 domestic facilities since the first patient was enrolled last August. The company anticipates completing enrollment by July this year. Once the target number of patients is reached, data analysis will take several months, during which preparations for the Phase 3 component will commence, aiming for a swift transition to the next phase.
The trial employs an innovative adaptive seamless design, unique in Japan, focusing on survival endpoints. Based on the degree of superiority observed in Phase 2, the sample size for Phase 3 could increase or decrease accordingly. This approach seeks to expedite the provision of cancer microenvironment improvement agent DFP17,729 to patients undergoing tertiary treatment for pancreatic cancer.
🟢 Confidence: High AI-translated content.